fingolimod hydrochloride has been researched along with Carcinoma, Pancreatic Ductal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hiramoto, M; Hirota, A; Kazama, H; Miyazaki, M; Miyazawa, K; Ogawa, M; Ota, K; Suzuki, S; Takano, N | 1 |
| Abdel-Salam, MML; Ahmad, SA; Bachmann, M; Becker, KA; Carpinteiro, A; Gulbins, E; Kadow, S; Keitsch, S; Patel, SH; Soddemann, M; Szabo, I; Wilker, B; Wilson, GC; Xu, K | 1 |
2 other study(ies) available for fingolimod hydrochloride and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells.
Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Fingolimod Hydrochloride; Humans; Hydroxychloroquine; Lapatinib; Lysosomes; Pancreatic Neoplasms; Sphingosine 1 Phosphate Receptor Modulators | 2022 |
Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in vivo.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Lysosomes; Mitochondria; Pancreatic Ducts; Pancreatic Neoplasms; Sphingomyelin Phosphodiesterase; Sphingomyelins | 2023 |